- Record: found
- Abstract: not found
- Article: not found
Targeted drugs for metastatic renal cell carcinoma.
2007-12-22
Angiogenesis Inhibitors, adverse effects, pharmacology, therapeutic use, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Carcinoma, drug therapy, mortality, secondary, Costs and Cost Analysis, Double-Blind Method, Humans, Indoles, Interferon-alpha, Kidney Neoplasms, Pyrroles, Recombinant Proteins, Sirolimus, analogs & derivatives, Survival Analysis, Vascular Endothelial Growth Factor A, drug effects
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Author and article information
Angiogenesis Inhibitors,adverse effects,pharmacology,therapeutic use,Antibodies, Monoclonal,Antibodies, Monoclonal, Humanized,Carcinoma,drug therapy,mortality,secondary,Costs and Cost Analysis,Double-Blind Method,Humans,Indoles,Interferon-alpha,Kidney Neoplasms,Pyrroles,Recombinant Proteins,Sirolimus,analogs & derivatives,Survival Analysis,Vascular Endothelial Growth Factor A,drug effects
Angiogenesis Inhibitors, adverse effects, pharmacology, therapeutic use, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Carcinoma, drug therapy, mortality, secondary, Costs and Cost Analysis, Double-Blind Method, Humans, Indoles, Interferon-alpha, Kidney Neoplasms, Pyrroles, Recombinant Proteins, Sirolimus, analogs & derivatives, Survival Analysis, Vascular Endothelial Growth Factor A, drug effects